journal
MENU ▼
Read by QxMD icon Read
search

Lancet Oncology

journal
https://www.readbyqxmd.com/read/30017351/robot-assisted-laparoscopic-prostatectomy-versus-open-radical-retropubic-prostatectomy-24-month-outcomes-from-a-randomised-controlled-study
#1
Geoffrey D Coughlin, John W Yaxley, Suzanne K Chambers, Stefano Occhipinti, Hema Samaratunga, Leah Zajdlewicz, Patrick Teloken, Nigel Dunglison, Scott Williams, Martin F Lavin, Robert A Gardiner
BACKGROUND: Previous trials have found similar early outcomes after robot-assisted laparoscopic prostatectomy and open radical retropubic prostatectomy. We report functional and oncological postoperative outcomes up to 24 months after surgery for these two surgical techniques. METHODS: In this randomised controlled phase 3 study, men who had newly diagnosed clinically localised prostate cancer and who had chosen surgery as their treatment approach, and were aged between 35 years and 70 years were eligible and recruited from the Royal Brisbane and Women's Hospital (Brisbane, QLD, Australia)...
July 12, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30017350/much-ado-about-robotic-versus-open-radical-prostatectomy
#2
Vidit Sharma, R Jeffrey Karnes
No abstract text is available yet for this article.
July 12, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30017349/systemic-therapy-after-ifrt-for-follicular-lymphoma
#3
Priya Venkatesan
No abstract text is available yet for this article.
July 12, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30017348/growing-pains-for-us-proton-therapy
#4
Bryant Furlow
No abstract text is available yet for this article.
July 12, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30017347/cervical-hpv-testing-versus-cytology
#5
Talha Khan Burki
No abstract text is available yet for this article.
July 12, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30001990/safety-and-feasibility-of-ultrasound-triggered-targeted-drug-delivery-of-doxorubicin-from-thermosensitive-liposomes-in-liver-tumours-tardox-a-single-centre-open-label-phase-1-trial
#6
Paul C Lyon, Michael D Gray, Christophoros Mannaris, Lisa K Folkes, Michael Stratford, Leticia Campo, Daniel Y F Chung, Shaun Scott, Mark Anderson, Robert Goldin, Robert Carlisle, Feng Wu, Mark R Middleton, Fergus V Gleeson, Constantin C Coussios
BACKGROUND: Previous preclinical research has shown that extracorporeal devices can be used to enhance the delivery and distribution of systemically administered anticancer drugs, resulting in increased intratumoural concentrations. We aimed to assess the safety and feasibility of targeted release and enhanced delivery of doxorubicin to solid tumours from thermosensitive liposomes triggered by mild hyperthermia, induced non-invasively by focused ultrasound. METHODS: We did an open-label, single-centre, phase 1 trial in a single UK hospital...
July 9, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30001989/non-invasive-image-guided-targeted-drug-delivery
#7
Dieter Haemmerich
No abstract text is available yet for this article.
July 9, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30001988/targeting-vegf-and-egfr-a-combination-worth-re-exploring
#8
Vatche Tchekmedyian, Eric J Sherman
No abstract text is available yet for this article.
July 9, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30001987/pazopanib-plus-cetuximab-in-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-an-open-label-phase-1b-and-expansion-study
#9
Douglas Adkins, Paul Mehan, Jessica Ley, Marilyn J Siegel, Barry A Siegel, Farrokh Dehdashti, Xuntian Jiang, Noha N Salama, Kathryn Trinkaus, Peter Oppelt
BACKGROUND: Angiogenesis is a hallmark of head and neck squamous cell carcinoma (HNSCC), and a mechanism of resistance to EGFR inhibition. We investigated the safety and potential activity of pazopanib, an angiogenesis inhibitor, plus cetuximab, an EGFR inhibitor, in patients with recurrent or metastatic HNSCC. METHODS: We did an open-label, single-centre, dose-escalation phase 1b trial using a standard 3 + 3 design, followed by an expansion cohort phase. Eligible participants were patients with histologically or cytologically confirmed recurrent or metastatic HNSCC, aged at least 18 years, had measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1...
July 9, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29983345/refametinib-in-ras-mutated-hepatocellular-cancer
#10
Manjulika Das
No abstract text is available yet for this article.
July 5, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29983344/enzalutamide-and-metastasis-risk-in-prostate-cancer
#11
Elizabeth Gourd
No abstract text is available yet for this article.
July 5, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29983343/fruquintinib-for-previously-treated-metastatic-colorectal-cancer
#12
Talha Khan Burki
No abstract text is available yet for this article.
July 5, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29960848/relapse-of-wilms-tumour-and-detection-methods-a-retrospective-analysis-of-the-2001-renal-tumour-study-group-international-society-of-paediatric-oncology-wilms-tumour-protocol-database
#13
Jesper Brok, Marta Lopez-Yurda, Harm V Tinteren, Taryn D Treger, Rhoikos Furtwängler, Norbert Graf, Christophe Bergeron, Marry M van den Heuvel-Eibrink, Kathy Pritchard-Jones, Øystein E Olsen, Beatriz de Camargo, Arnauld Verschuur, Filippo Spreafico
BACKGROUND: Wilms' tumour is the most common renal cancer in childhood and about 15% of patients will relapse. There is scarce evidence about optimal surveillance schedules and methods for detection of tumour relapse after therapy. METHODS: The Renal Tumour Study Group-International Society of Paediatric Oncology (RTSG-SIOP) Wilms' tumour 2001 trial and study is an international, multicentre, prospective registration, biological study with an embedded randomised clinical trial for children with renal tumours aged between 6 months and 18 years...
June 27, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29960847/optimising-surveillance-for-relapse-of-wilms-tumour
#14
Harold N Lovvorn
No abstract text is available yet for this article.
June 27, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29941280/addition-of-dose-intensified-doxorubicin-to-standard-chemotherapy-for-rhabdomyosarcoma-epssg-rms-2005-a-multicentre-open-label-randomised-controlled-phase-3-trial
#15
Gianni Bisogno, Meriel Jenney, Christophe Bergeron, Soledad Gallego Melcón, Andrea Ferrari, Odile Oberlin, Modesto Carli, Michael Stevens, Anna Kelsey, Angela De Paoli, Mark N Gaze, Helene Martelli, Christine Devalck, Johannes H Merks, Myriam Ben-Arush, Heidi Glosli, Julia Chisholm, Daniel Orbach, Veronique Minard-Colin, Gian Luca De Salvo
BACKGROUND: Rhabdomyosarcoma is an aggressive tumour that can develop in almost any part of the body. Doxorubicin is an effective drug against rhabdomyosarcoma, but its role in combination with an established multidrug regimen remains controversial. Therefore, we aimed to evaluate the possible benefit of early dose intensification with doxorubicin in patients with non-metastatic rhabdomyosarcoma. METHODS: We did a multicentre, open-label, randomised controlled, phase 3 trial involving 108 hospitals from 14 countries...
June 22, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29937394/new-genetic-discoveries-in-prostate-cancer
#16
Elizabeth Gourd
No abstract text is available yet for this article.
June 21, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29937393/urologists-reduce-overtreatment-in-prostate-cancer
#17
Manjulika Das
No abstract text is available yet for this article.
June 21, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29914797/convection-enhanced-delivery-chemosurgery-in-diffuse-intrinsic-pontine-glioma
#18
Dannis G van Vuurden
No abstract text is available yet for this article.
June 15, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29914796/convection-enhanced-delivery-for-diffuse-intrinsic-pontine-glioma-a-single-centre-dose-escalation-phase-1-trial
#19
Mark M Souweidane, Kim Kramer, Neeta Pandit-Taskar, Zhiping Zhou, Sofia Haque, Pat Zanzonico, Jorge A Carrasquillo, Serge K Lyashchenko, Sunitha B Thakur, Maria Donzelli, Ryan S Turner, Jason S Lewis, Nai-Kong V Cheung, Steven M Larson, Ira J Dunkel
BACKGROUND: Diffuse intrinsic pontine glioma is one of the deadliest central nervous system tumours of childhood, with a median overall survival of less than 12 months. Convection-enhanced delivery has been proposed as a means to efficiently deliver therapeutic agents directly into the brainstem while minimising systemic exposure and associated toxic effects. We did this study to evaluate the safety of convection-enhanced delivery of a radioimmunotherapy agent targeting the glioma-associated B7-H3 antigen in children with diffuse intrinsic pontine glioma...
June 15, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29909947/concurrent-chemotherapy-improves-outcomes-in-hnscc
#20
Elizabeth Gourd
No abstract text is available yet for this article.
June 14, 2018: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"